Literature DB >> 32474674

Hepatoprotective effect and possible mechanism of phytoestrogen calycosin on carbon tetrachloride-induced liver fibrosis in mice.

Mengmeng Zhang1, Yaxin Wang1, Guannan Zhu1, Cheng Sun1, Jiajia Wang2.   

Abstract

The study was to explore the hepatoprotective effect and possible mechanism of calycosin on carbon tetrachloride (CCl4)-induced liver fibrosis in mice. Hepatic fibrosis was induced by intraperitoneal injection of CCl4 in C57BL/6 male mice. Serum alanine aminotransferase (ALT) and aspartate transaminase (AST) activity, superoxide dismutase (SOD) activity, and hydroxyproline (Hyp) and malondialdehyde (MDA) levels were determined by biochemical assays. Liver histopathology was assessed by H&E and Masson trichrome staining. The mRNA expressions of α-smooth muscle actin (α-SMA), collagen-I (Col-I), Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) were determined using qRT-PCR. The protein levels of α-SMA, Col-I, estrogen receptor α (ERα), estrogen receptor β (ERβ), tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-1 (MMP-1), JAK2, phospho-JAK2 (p-JAK2), STAT3, and phospho-STAT3 (p-STAT3) were detected by Western blotting. The levels of α-SMA and ERβ were measured by immunohistochemistry. Calycosin significantly reduced liver index, MDA level, and ALT and AST activity and increased SOD activity. The α-SMA, Col-I, and Hyp of the calycosin group were significantly lower than those of the model group. Calycosin increased MMP-1 and inhibited TIMP-1 expression resulting in the improvement of MMP-1/TIMP-1 ratio. Importantly, calycosin improved ERβ protein expression, JAK2 and STAT3 mRNA expressions, p-JAK2/JAK2, and p-STAT3/STAT3 relative protein expressions. However, ERα, JAK2, and STAT3 protein expressions were relatively unchanged. Calycosin significantly inhibits liver fibrosis in mice, and its mechanism may involve the following: calycosin inhibits oxidative stress; calycosin inhibits collagen synthesis and balances MMP-1/TIMP-1 system; calycosin increases ERβ expression and activates JAK2-STAT3 pathway.

Entities:  

Keywords:  Calycosin; Estrogen receptor; Hepatoprotective; JAK-STAT pathway; Liver fibrosis; Matrix metalloproteinase

Year:  2020        PMID: 32474674     DOI: 10.1007/s00210-020-01891-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  56 in total

Review 1.  A road map for those who don't know JAK-STAT.

Authors:  David S Aaronson; Curt M Horvath
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  Carbenoxolone ameliorates hepatic lipid metabolism and inflammation in obese mice induced by high fat diet via regulating the JAK2/STAT3 signaling pathway.

Authors:  Yuning Chen; Wen Lu; Zhengyu Jin; Jian Yu; Bimin Shi
Journal:  Int Immunopharmacol       Date:  2019-06-29       Impact factor: 4.932

3.  Protective effects of calycosin against CCl4-induced liver injury with activation of FXR and STAT3 in mice.

Authors:  Xinli Chen; Qiang Meng; Changyuan Wang; Qi Liu; Huijun Sun; Xiaokui Huo; Pengyuan Sun; Xiaobo Yang; Jinyong Peng; Kexin Liu
Journal:  Pharm Res       Date:  2014-08-21       Impact factor: 4.200

4.  Inhibition effect of phytoestrogen calycosin on TGF-β1-induced hepatic stellate cell activation, proliferation, and migration via estrogen receptor β.

Authors:  Tan Deng; Jing Liu; Mengmeng Zhang; Yaxin Wang; Guannan Zhu; Jiajia Wang
Journal:  Can J Physiol Pharmacol       Date:  2018-10-12       Impact factor: 2.273

5.  Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis.

Authors:  Jérôme Avouac; Barbara G Fürnrohr; Michal Tomcik; Katrin Palumbo; Pawel Zerr; Angelika Horn; Clara Dees; Alfiya Akhmetshina; Christian Beyer; Oliver Distler; Georg Schett; Yannick Allanore; Jörg H W Distler
Journal:  Arthritis Rheum       Date:  2011-03

6.  Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells.

Authors:  Qi Cao; Ki M Mak; Charles S Lieber
Journal:  J Hepatol       Date:  2006-09-22       Impact factor: 25.083

7.  Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy.

Authors:  Liana Codes; Tarik Asselah; Dominique Cazals-Hatem; Florence Tubach; Dominique Vidaud; Raymundo Paraná; Pierre Bedossa; Dominique Valla; Patrick Marcellin
Journal:  Gut       Date:  2006-09-27       Impact factor: 23.059

Review 8.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

9.  Kefir peptides prevent high-fructose corn syrup-induced non-alcoholic fatty liver disease in a murine model by modulation of inflammation and the JAK2 signaling pathway.

Authors:  H L Chen; T C Tsai; Y C Tsai; J W Liao; C C Yen; C M Chen
Journal:  Nutr Diabetes       Date:  2016-12-12       Impact factor: 5.097

10.  CXCL6-EGFR-induced Kupffer cells secrete TGF-β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/EZH2 pathway in liver fibrosis.

Authors:  Xiaobo Cai; Zhenghong Li; Qidi Zhang; Yin Qu; Mingyi Xu; Xinjian Wan; Lungen Lu
Journal:  J Cell Mol Med       Date:  2018-08-14       Impact factor: 5.310

View more
  2 in total

1.  Calycosin Ameliorates Bleomycin-Induced Pulmonary Fibrosis via Suppressing Oxidative Stress, Apoptosis, and Enhancing Autophagy.

Authors:  Haoge Liu; Xiaoxu Bai; Wan Wei; Zhipeng Li; Zhengju Zhang; Weili Tan; Bin Wei; Hantao Zhao; Yang Jiao
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

2.  Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation.

Authors:  Yaxin Wang; Canyan Wu; Jiahui Zhou; Haiming Fang; Jiajia Wang
Journal:  BMC Pharmacol Toxicol       Date:  2022-10-07       Impact factor: 2.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.